Cross-Sectional Analysis of Research and Non-Research Payments From the Medical Device Industry to Healthcare Professionals and Organisations in Japan in 2022

IF 2.1 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Journal of evaluation in clinical practice Pub Date : 2025-03-26 DOI:10.1111/jep.70066

Anju Murayama

{"title":"Cross-Sectional Analysis of Research and Non-Research Payments From the Medical Device Industry to Healthcare Professionals and Organisations in Japan in 2022","authors":"Anju Murayama","doi":"10.1111/jep.70066","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Rationale</h3>\n \n <p>Financial relationships between healthcare professionals (HCPs), healthcare organisations (HCOs) and the medical device industry in Japan may lead to conflicts of interest. Limited transparency in these relationships has raised concerns regarding their potential influence on clinical decision-making and patient care.</p>\n </section>\n \n <section>\n \n <h3> Aims and Objectives</h3>\n \n <p>This study aimed to assess the scope and magnitude of financial payments from medical device companies to HCPs and HCOs in Japan, focusing on publicly disclosed data from the 2022 fiscal year.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A cross-sectional analysis of publicly available payment disclosures from 169 medical device companies, including all members of the Japan Federation of Medical Devices Associations (JFMDA) and several major non-JFMDA affiliated companies, was conducted. Descriptive statistics were calculated to summarise payment data.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 169 medical device companies, 32.5% (55 companies) did not disclose payment information and 6 companies disclosed payment records in aggregated amounts with their group companies, leaving 108 companies for analysis. In total, $245.2 million in payments were made in 2022, with only 23.9% ($58.7 million) to research and development. Of the total, 34.6% ($84.9 million) was allocated to non-research payments to HCOs for sponsoring HCOs’ activities, and 19.6% ($49.0 million) were paid for lecturing and consulting fees, typically to individual HCPs. More than 80% of companies allocated a greater share of payments to non-research activities than to research.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study reveals substantial financial relationships between medical device companies and HCPs/HCOs in Japan, predominantly for non-research purposes. Improved transparency regulations, including a uniform, government-run database, are necessary to better oversee these financial interactions with medical device industry in Japan.</p>\n </section>\n </div>","PeriodicalId":15997,"journal":{"name":"Journal of evaluation in clinical practice","volume":"31 2","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jep.70066","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of evaluation in clinical practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jep.70066","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Rationale

Financial relationships between healthcare professionals (HCPs), healthcare organisations (HCOs) and the medical device industry in Japan may lead to conflicts of interest. Limited transparency in these relationships has raised concerns regarding their potential influence on clinical decision-making and patient care.

Aims and Objectives

This study aimed to assess the scope and magnitude of financial payments from medical device companies to HCPs and HCOs in Japan, focusing on publicly disclosed data from the 2022 fiscal year.

Methods

A cross-sectional analysis of publicly available payment disclosures from 169 medical device companies, including all members of the Japan Federation of Medical Devices Associations (JFMDA) and several major non-JFMDA affiliated companies, was conducted. Descriptive statistics were calculated to summarise payment data.

Results

Of the 169 medical device companies, 32.5% (55 companies) did not disclose payment information and 6 companies disclosed payment records in aggregated amounts with their group companies, leaving 108 companies for analysis. In total, $245.2 million in payments were made in 2022, with only 23.9% ($58.7 million) to research and development. Of the total, 34.6% ($84.9 million) was allocated to non-research payments to HCOs for sponsoring HCOs’ activities, and 19.6% ($49.0 million) were paid for lecturing and consulting fees, typically to individual HCPs. More than 80% of companies allocated a greater share of payments to non-research activities than to research.

Conclusion

This study reveals substantial financial relationships between medical device companies and HCPs/HCOs in Japan, predominantly for non-research purposes. Improved transparency regulations, including a uniform, government-run database, are necessary to better oversee these financial interactions with medical device industry in Japan.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of evaluation in clinical practice 医学-卫生保健

CiteScore

4.80

自引率

4.20%

发文量

143

审稿时长

3-8 weeks

期刊介绍： The Journal of Evaluation in Clinical Practice aims to promote the evaluation and development of clinical practice across medicine, nursing and the allied health professions. All aspects of health services research and public health policy analysis and debate are of interest to the Journal whether studied from a population-based or individual patient-centred perspective. Of particular interest to the Journal are submissions on all aspects of clinical effectiveness and efficiency including evidence-based medicine, clinical practice guidelines, clinical decision making, clinical services organisation, implementation and delivery, health economic evaluation, health process and outcome measurement and new or improved methods (conceptual and statistical) for systematic inquiry into clinical practice. Papers may take a classical quantitative or qualitative approach to investigation (or may utilise both techniques) or may take the form of learned essays, structured/systematic reviews and critiques.